Sutimlimab

N/A

Report date: 2026/03/31 20:00:21
First In Class

Base Information

Drug NameSutimlimab
Drug Alias NameSutimlimab-jomeENJAYMOTNT-009BIVV-009
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionComplement C1s inhibitors
TargetsComplement C1s
Therapy Area/IndicationsHemolysisPemphigoid, BullousPurpura, Thrombocytopenic, Idiopathic +[6] 
Global Approved IndicationsHemolysisAnemia, Hemolytic, Autoimmune
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2022/02/04
Country/TerritoryBelgiumCanadaUnited States +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesTrue North Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesBioverativ, A Sanofi CompanyRecordati Rare Diseases IncSanofi +[4] 
Inactive CompaniesGenzyme Europe Bv
Active IndicationsHemolysisAnemia, Hemolytic, Autoimmune
Inactive IndicationsPemphigoid, BullousPurpura, Thrombocytopenic, IdiopathicKidney Failure, Chronic +[4] 

Other Information

ATC CodeN/A
Related LinksN/A